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Nutrient sensing is a highly conserved process that evolved for cells to respond to 
nutrient availability and scarcity. In conditions of low nutrients, cells respond by reducing 
cellular processes involved in cell growth. The pathways regulating these responses 
revolve around TOR (target of rapamycin), which is a conserved protein in mammals 
(mTOR), yeast (Tor1 and Tor2) and Drosophila (dTOR). TOR activity decreases in 
response to low nutrients, but the complex nature of the pathways involved have left 
many questions unanswered. In particular, how amino acids are sensed to regulate cell 
growth is incompletely understood.   
Our lab identified WHI2 and the genes for most components of the ESCRT 
complexes in a genome-wide screen seeking to identify genes required to reduce cell 
growth in low amino acids. I pursued this thesis project to determine which specific 
amino acids, if any, were being sensed in a WHI2-dependent manner. Several media 
formulations were modified and new ones were developed to compare the growth of 
WHI2 and ESCRT knockout strains. Here I provide evidence that leucine is sensed in a 
ratio to other amino acids to regulate cell growth, and WHI2 is required for responding to 
low leucine concentrations. I also show that without WHI2, glutamic acid plays a critical 
role in regulating growth in low leucine concentrations, which could suggest a potential 





I would like to thank the MMI department for giving me this wonderful 
opportunity to further my interest in infectious diseases and expand my knowledge as a 
future scientist. My experiences through the program helped drive my interest in public 
health and prepare me for my future endeavors. In particular, I would like to thank Dr. 
Marie Hardwick for being a wonderful mentor to me not only during my graduate 
studies, but also while I was an undergraduate student. My conversations with Dr. 
Hardwick helped me learn about experiments I could further pursue and gave me 
different perspectives in interpreting my results. She was also an inspiration for me to 
further pursue research.  Aside from her guidance and mentorship, I would also like to 
thank everyone in the lab for their friendship, mentorship, and suggestions that helped 
develop my project. I would like to thank Dr. Heather Lamb for her mentorship when I 
was an undergraduate student, Kyle Metz for his guidance in cell culture and cloning, and 
Tim Wang for his help and guidance with my experiments. I especially appreciate Dr. 
Xinchen Teng for mentoring me in yeast work and answering my questions even when 
she was situated in China. Additionally, I would like to thank my friends, especially Jared 
Balaich and Rebecca Yee, who have supported me through this entire journey. I 
appreciate their help and insights in addition to the laughs provided to ease my stress. 
Lastly, I would like to thank my family for their unwavering support and love. For all the 
hardships they have gone through to allow me to pursue my education and career goals, I 
hope I can one day provide and support them in any way they need. My love for my 
family cannot be properly expressed in words. I would also like to thank Dr. Kyle 




Table of Contents 
 
Title Page ............................................................................................................................. i 
Abstract ............................................................................................................................. ii 
Table of Contents .............................................................................................................. iv 
List of Tables ...................................................................................................................... v 
List of Figure ..................................................................................................................... vi 
Chapter 1: Introduction to TOR, WHI2, and autophagy .............................................. 1 
Target of Rapamycin ................................................................................................................. 1 
WHI2 in cell growth and autophagy ....................................................................................... 10 
Chapter 2: Materials and Methods ................................................................................ 17 
Yeast Strains and Media .......................................................................................................... 17 
Yeast Serial Dilution Plating ................................................................................................... 18 
Plasmid Transformation .......................................................................................................... 19 
Chapter 3: Leucine is sensed in a ratio with other amino acids to regulate cell 
growth ............................................................................................................................... 24 
Introduction .............................................................................................................................. 24 
Results ....................................................................................................................................... 25 
Chapter 4: Glutamic acid is sufficient to rescue Δwhi2 strain overgrowth on 
SCDMEDD ........................................................................................................................... 45 
Results ....................................................................................................................................... 45 
Chapter 5: Discussion Of Results and Future Directions ............................................ 55 
Discussion of Results ................................................................................................................ 55 
Future Directions ..................................................................................................................... 61 
References ........................................................................................................................ 64 
Appendix 1: Modified SCD recipes and experimental replicate information ........... 70 




List of Tables 
 
Table 1 : Yeast strains used in this study ...................................................................... 20 




List of Figures 
 
Figure 1 : TOR complexes in mammalian and yeast cells ........................................... 13 
Figure 2 : Upstream pathway in amino acid dependent activation of mTORC1 ...... 14 
Figure 3 : TORC1/mTORC1 downstream pathways ................................................... 15 
Figure 4 : Alignment of N-terminal end of yeast Whi2 and human KCTDs ............. 16 
Figure 5 : Defining plate nomenclature used in experiments ...................................... 23 
Figure 6 : Low leucine restricts growth in the WT strains, but not the Δwhi2 or 
ESCRT complex KO strains ....................................................................... 30 
Figure 7 : Overgrowth by Δwhi2 and ESCRT complex KO strains not dependent on 
total amino acid concentrations .................................................................. 31 
Figure 8 : Leucine contribution of less than 4% by weight to total amino acid 
concentration may act as threshold of overgrowth phenotype ................ 32 
Figure 9 : Low leucine ratio to other amino acids restricts WT growth but not for 
Δwhi2 and ESCRT KO strains .................................................................... 34 
Figure 10 : Leucine is sensed in a ratio with other amino acids even at low 
concentrations ............................................................................................... 39 
Figure 11 ; Leucine concentration independent of other amino acids, does not 
account for overgrowth phenotype ............................................................. 40 
Figure 12 : Overgrowth phenotype by whi2 and ESCRT mutants is not due to 
leucine being an auxotrophic amino acid ................................................... 42 
Figure 13 : Low leucine overgrowth phenotype for the Δwhi2 or ESCRT complex 
KO strain requires more than leucine and a single amino acid addition43 
Figure 14 : Adding back combinations of amino acids have yet to reveal overgrowth 
phenotype on SCDAux ................................................................................... 44 
Figure 15 : WHI2 but not most ESCRTs are required to respond to low levels of the 
non-essential glutamic acid ......................................................................... 48 
Figure 16 : Glutamic acid is the only amino acid that has an effect on the difference 
in Δwhi2 overgrowth between SCDME and SCDMEDD ............................... 50 
Figure 17 : Other changes to SCDMEDD when adding glutamic acid does not rescue 
Δwhi2 overgrowth ........................................................................................ 52 
Figure 18 : WHI2 complementation in the Δwhi2 strain restores WT-like growth 






Introduction to TOR, WHI2, and autophagy 
 
Target of Rapamycin 
Nutrient sensing is a highly conserved physiological process across essentially all 
living organisms due to the evolution pressure presented by nutrient scarcity [1]. When 
amino acid levels in the extracellular environment are low, both mammalian and yeast 
cells downregulate molecular processes associated with cell growth, such as transcription 
and translation, while upregulating processes involved in degradation and recycling, such 
as macroautophagy [1, 2]. The central hub for regulating cell growth in response to 
nutrient availability is the target of rapamycin (TOR) protein, a large serine/threonine 
kinase [2–4]. Because several aspects of this pathway are conserved, yeast are a useful 
model for understanding basic the biology and for delineating potential targets for 
controlling pathogenic yeast strains.  
Saccharomyces cerevisiae have two genes, TOR1 and TOR2, encoding two 
similar proteins belonging to two different complexes that regulate complementary 
aspects of cellular growth [4]. Tor1 and Tor2 form the TORC1 (Tor complex 1) and 
TORC2 (Tor complex 2) [4]. Conversely, mammalian cells only encode one TOR 
protein, mTOR (mammalian/mechanistic target of rapamycin) [5]. The single TOR 
protein in mammals forms the two distinct complexes, mTORC1 (mTOR complex 1) and 
mTORC2 (mTOR complex 2) [2, 6, 7]. When activated, mTORC1/TORC1 trigger 




autophagy, while TORC2/mTORC2 results in increased cell survival, metabolism and 
actin polymerization and reorganization.[5] 
 
TORC1 
While yeast and mammalian TOR complexes have similar functions, the 
components between the yeast and mammalian complexes are only partially conserved. 
In mTORC1, mTOR is bound to Tti1/Tel2 (believed to be a scaffolding protein), mLST8 
(the mTOR-associated protein, Lethal with SEC thirteen, yeast Lst8 homolog) and two 
kinase inhibitors, DEPTOR (DEP domain containing mTOR-interacting protein) and 
PRAS40 (a proline-rich Akt substrate of 49 kDa, also called AKT1S1) [2, 7]. mTORC1 
also contains RAPTOR (regulatory associated protein of mTOR), while mTORC2 is 
distinguished by containing RICTOR (rapamycin-insensitive companion of mTOR) (Fig. 
1a) [2, 3]. Yeast TORC1 consists of Tor1 bound to TCO89, Lst8 and Kog1, the yeast 
homologue of RAPTOR (Fig. 1b) [4]. 
 
mTORC1 and TORC1 upstream interactions 
As a master regulator of cellular growth, there are many upstream pathways that 
activate mTORC1/TORC1. However, many of the activating signals converge on the 
small GTPase Rheb (Ras homolog enriched in brain) [2]. Rheb is found in both 
mammalian and yeast cells and when activated, acts to activate mTORC1/TORC1, but 
the mechanism is still unclear [8, 9]. GTP-bound Rheb is believed to upregulate 
mTORC1 activity by preventing the association of mTORC1 with FKBP38, a protein 




cells, directly upstream of the Rheb GTPase is the negative regulator complex, a dimer of 
TSC1 (tuberous sclerosis complex 1) and TSC2 [2]. It has been shown that TSC2 acts as 
a negative regulator of Rheb through its selective GAP activity towards Rheb, which 
lowers the amount of GTP-bound Rheb [9].  
 Upstream of the TSC1/2 and Rheb axis is the protein kinase Akt, which is also 
called PKB (protein kinase B) [4]. Akt is activated through phosphorylation by PDK1 (3-
phosphoinositide-dependent protein kinase-1) and PDK2 [4, 9]. However, aside from the 
direct phosphorylation of Akt by the PDK kinases, the action of TORC2 is also required 
[4]. TORC2 can phosphorylate the same site as PDK2 on Akt, which promotes 
phosphorylation by PDK1 [4]. The activation of Akt is believed to be insulin-dependent, 
and plays an important role in glucose uptake of the cell [11]. It is believed that cell 
membrane RTKs (receptor tyrosine kinases), GPCRs (G-protein-coupled receptors), and 
cytokine receptors activate PI3K (phsophoinositide 3-kinase), which will phosphorylate 
membrane phosphatidylinositol lipids, such as PDK1 and PDK2, that lead to the 
activation of Akt [11]. The importance of Akt in insulin-signaling and glucose uptake 
points towards the Rheb/TSC1/2 axis activation of TOR playing a larger role in response 
to glucose than to amino acids.  
 
Amino Acid Sensing Upstream of mTORC1/TORC1 
Recent biochemical dissection of amino acid-dependent activation of TOR has 
been done best in mammalian systems, but many of these factors were first identified 
through yeast genetic studies [2]. Leucine has been shown to play an important role in 




cells do not activate TOR in the presence of only leucine [2]. However, the other amino 
acids that play a role with leucine to regulate growth are still unknown, although 
glutamine cotransport with leucine has been reported in mammalian cells [2]. Research 
from several groups suggest that the lysosome (yeast vacuole), the primary subcellular 
reservoir of amino acids, is the site where amino acids are sensed to regulate TOR 
activity and growth in mammalian and yeast cells [11–16]. Supporting these claims, 
mTORC1/TORC1 is commonly localized to these organelles [2, 17].  
The proteins that control mTORC1 localization to the lysosome are the GTPase 
heterodimers Rag A/B and Rag C/D [2]. When the cell is deprived of amino acids, 
RagA/B  binds GDP, which is exchanged for GTP when the cell is no longer starved of 
amino acids [2]. This binding of GTP recruits both the Rag heterodimers and mTORC1 
to the lysosomal membrane [2]. Although yeast TORC1 is constitutively localized to the 
vacuole membrane, the Rag orthologs in yeast, Gtr1 (GTP binding related 1) and Gtr2, 
also activate TORC1 when amino acids are abundant [2, 3].  
While the Rag proteins and the Gtr proteins are important for activating 
mTORC1, these proteins do not contain lipid localization domains to guide them to the 
lysosomal or vacuolar membrane [2]. The localization process is controlled in 
mammalian cells by a complex called the Ragulator, with the functional analog in 
budding yeast, S. cerevisiae, suggested to be the heterodimeric complex called EGO1/3 
[2, 18]. The Ragulator complex preferentially binds to the inactivated, unbound or GDP-
bound RagA/B complex, and consequently loads a GTP into the complex (Fig. 2), 
activating the Rag heterodimers [2]. In yeast, it is believed that the EGO complex plays a 




structural similarity of Ego3 to components of the Ragulator complex, as well as the 
lipidation of Ego1 suggest that it also plays a role in tethering the Gtr proteins to the 
vacuole [3, 18]. However, a separate GEF and not the EGO complex has been proposed 
to activate Gtr1 [3]. 
These factors function proximally in the TOR pathway to respond to amino acids 
levels, but less is known about the upstream pathway. It was discovered, through 
screening dTORC1 interactors, that V-ATPase is required to control Ragulator function 
[2]. However, how it regulates the Ragulator complex is still unknown, as its established 
role in acidifying lysosomes does not appear to be important in amino acid regulation of 
mTORC1 [2]. In yeast, V-ATPase not only plays a similar function in acidifying the 
vacuole, it has also been shown to play an important role in vacuole permeabilization in 
cell death [20]. While this permeabilization occurs in yeast cellular death, V-ATPase may 
play a similar role in TOR activation by allowing certain amino acids to move through a 
permeabilized vacuolar membrane and activating upstream TOR pathways. 
Under low nutrient conditions, the GATOR1 complex inactivates RagA/B by 
stimulating hydrolysis of bound GTP, as inhibition of GATOR1 caused cells to have 
constitutively active mTORC1 even in low amino acid conditions [2, 20]. The GATOR1 
complex consists of DEPDC5, Nprl2, Nprl3, which is inhibited by the GATOR2 
complex, comprised of Mios, WDR2, WDR59, Seh1L, Sec13, and most of these have 
yeast orthologs [2, 20]. Yeast Npr2/3 were previously identified in a yeast screen for 
genes required to respond to nitrogen starvation, and were also identified in our lab’s 




The Sabatini group also recently discovered a putative arginine transporter, called 
SLC38A9.1, on the lysosomal membrane that regulates the process of GTR activation by 
GATOR1 (Fig. 2) [14]. SLC38A9.1 was shown to have arginine transport capability, and 
the non-membrane associated end seems to preferentially bind to GDP-bound RagA/B, 
similarly to the Ragulator [2, 13]. When considered together, the hypothesis made by the 
Sabatini group is that the binding of arginine, and possibly leucine, could lead to a 
conformational change in the membrane-associated domain [14]. This change in 
conformation could be relayed to the Ragulator to activate the Rag heterodimers, but the 
mechanisms behind this are still unknown [14]. Even with the discovery of this gene, 
there is still incomplete information about how other amino acids are sensed to activate 
TORC1 and how the activation occurs.  
 
mTORC1/TORC1 downstream effectors 
Although it is unclear how nutrient conditions are sensed by mTORC1/TORC1, 
the downstream effectors of TOR activation leading to cellular growth are also actively 
studied. The activation of mTORC1/TORC1 leads to the direct phosphorylation of 
several targets, including Sch9 and Tap42 [4, 8, 21–23]. The phosphorylation of these 
proteins leads to the cellular processes involved in growth [4, 8, 21–23]. 
Sch9 in yeast, and S6 kinase (S6K) in mammalian cells, is the primary kinase that 
bridges TORC1 activation and protein translation [4, 8, 21–23]. In mammalian cells, 
activation of S6K has been implicated in promoting of increased of 5’-terminal 
oligopyrimidine tracts (5’TOP) mRNA translation, which exclusively encodes for 




through phosphorylation of downstream effectors, such as the conserved ribosomal 
protein S6 [8]. In yeast, upon TORC1 activation, Sch9 becomes activated through direct 
phosphorylation by TOR, which goes on to phosphorylate the ribosomal protein S6 [4, 
23]. While presumed to have a role in translation, the role of phosphorylated S6 is still 
debated as some studies have shown that other kinases can phosphorylate S6 in a TOR 
knockout system [8]. Another target of activated S6K/Sch9 is the phosphorylation of 
eIF4B, which goes on to promote cell growth and proliferation (Fig. 3) [8]. 
In yeast and mammalian cells, Tap42 acts in a complex with PP2A (protein 
phosphatase 2a) directly downstream of TORC1 to regulate a wide variety of cellular 
functions [22, 23]. The Tap42-PP2A complex regulates amino acid synthesis and 
nitrogen through proteins such as Npr1, Gln3 (Glutamine metabolism 3), Rtg1/Rtg3 and 
other factors (Fig. 3) [23]. Additionally, the complex also regulates cellular responses to 
environmental stress through the Msn2/Msn4 pathway (Fig. 3) [23]. Tap42 has been 
shown to repress these pathways when activated TORC1 directly phosphorylates Tap42 
to stimulate binding to PP2A, consequently inactivating PP2A’s role in the amino acid 
synthesis and autophagy pathways (Fig. 3) [24].  
Tap42 has also been implicated in regulating the autophagy pathway through the 
Atg13-Atg1 complex, but there is conflicting data suggesting that Tap42 may not be 
necessary in autophagy induction upon TORC1 inactivation [23–25]. This link between 
autophagy and TOR is of particular interest to this project as Whi2, a yeast gene, has 
been shown to play a role in autophagy function [27]. Autophagy is a process the cell 
undergoes to degrade micronutrients or damaged cellular components for reuse in other 




phosphorylated Atg13, preventing it from forming the Atg1-Atg13 complex required to 
induce autophagy [25]. On the other hand, the Klionsky group showed that upon 
inactivation of PP2A via Tap42, Atg1 is indirectly inhibited through an unknown 
mechanism [26]. These findings thus make the role of Tap42 in autophagy regulation 
unclear.  
The pathways controlled by TORC1 activation lead to increased translation and 
transcription through Sch9 and Tap42 activation, and decreased autophagy through 
phosphorylation of the Atg1-Atg13 complex. The regulation of these pathways is 
particularly important so that the catabolic processes upregulated by TORC1 are not 
immediately degraded by the autophagic process, and conversely, when the cell is not 
actively synthesizing new molecules, the autophagy process can provide recycled 
nutrients needed to sustain cellular functions [6]. 
Interestingly, a recent study has shown that the downstream effectors of TORC1 
activation are partially dependent on the nutrient source that is regulating TORC1 [23]. 
While rapamycin exposure or nitrogen starvation did not downregulate the PP2A 
pathway, glucose starvation conditions resulted in only weakly activated PP2A pathways 
[23]. However, regardless of starvation and stress conditions, the Sch9 pathway was 
inhibited [23]. This effect was regulated by the upstream activators of TORC1, Gtr1/2, 
Npr2/3, and Rho1 (a protein involved in TORC1 and PP2A association), which are 
involved in TOR1 activation in a nitrogen/amino acid-dependent manner. Snf1 plays a 
critical role in shutting off TORC1 in glucose-deprived environments, while Hog1 was 
identified as a stress-activated protein that inactivates TORC1 in response to osmotic 




it ties the growth phenotype to specific types of starvation or stress encountered by the 
cell. While this ties the upstream effectors of TORC1 to the downstream response 






WHI2 in cell growth and autophagy 
WHI2 was reported to be a fungal-specific gene discovered in the late 1980’s [29]. 
Little is known about WHI2 except that it plays roles in regulation of cell morphology, 
stress responses and control of cell growth [26, 29–32]. One reason that WHI2 is poorly 
studied is because it was believed to lack homologues or orthologs in humans. However, 
our lab reported that Whi2 is homologous (predicted to have a common ancestor) to a 
family of 25 human KCTD (potassium channel tetramerization domain) proteins, due to 
similarities in the BTB domain (Fig 4) [34]. 
Many of the known downstream effectors of Whi2 are involved in the stress 
response and cell growth [28–30]. Whi2 is reported to be involved with the 
phosphorylation of the stress response-related transcription factor Msn2, as well as the 
plasma membrane-associated phosphatase Psr1 [34, 35]. A study indicated that in cells 
deleted for WHI2, Msn2 was found to be hyperphosphorylated [36]. Both Psr1 and Msn2 
are necessary for activating the stress response.  
Most of the early literature about WHI2 was from the Sudbury group, which 
showed that cells with whi2 mutations tended to grow faster, and were smaller in size, 
than wild-type cells when grown in ethanol [37]. Additionally, in carbon starvation 
conditions, the whi2 mutant cells did not arrest cellular growth like the wild type cells 
due to dysregulation of the G1 cyclins, CLN1 and CLN2 [37]. The Sudbury group, using 
glucosamid and glucose to tease apart the regulation of growth due to low glucose or 
catabolite repression in whi2 mutants, came to the conclusion that Whi2 plays a role as a 
negative regulator of cell growth [31]. Lastly, their group showed that overexpression of 




morphology, which may be the result of improper budding [30, 31]. A recent study on 
Pus1, a protein involved in yeast gene splicing, reported that PUS1 overexpression also 
resulted in filamentous growth [35]. The presence of a STRE (stress response element) 
promoter region upstream of PUS1, seems to indicate that growth and division may be 
regulated by Whi2 and its interacting partner Psr1 in the stress-response pathway [35].  
Two recent studies on WHI2 disagree on its role in autophagy, in particular its 
role in mitophagy. Autophagy is classified into three main types, macroautophagy, 
microautophagy, and mitophagy, which is a similar process targets mitochondria for 
degradation via the autophagosome [38]. Macroautophagy focuses on recycling and 
degrading damaged organelles, cytosolic proteins and invasive microbes, through capture 
by a specialized vesicle called the autophagosome [39]. Conversely, microautophagy 
directly uptakes degradation targets by the vacuole or lysosome, and typically targets 
soluble components, but can help degrade damaged organelles [39, 40].  
The link between Whi2 and mitophagy was suggested by the Reichert group, who 
reported a mitophagy defect in the Dfis1 deletion strain. They attributed the mitophagy 
defect to the secondary mutation in whi2 that was previously reported by our lab to occur 
in Dfis1 strains [26, 32]. Reichert and colleagues showed that mitophagy, and to a certain 
extent autophagy, was not as robustly induced in a Δwhi2 strain when Tor1 was inhibited 
by rapamycin [27]. The decrease in mitophagy was rescued in both the Δfis1 and Δwhi2 
strains with the complementation of WHI2, but not FIS1 [27]. A mitophagy defect is also 
suggested by the electron microscopy images our lab reported for the Dfis1 deletion 
strain [42]. This also seems to be confirmed with a higher prevalence of mitochondria 




is consistent with our lab’s earlier report that a mutation in whi2 rescues mitochondrial 
phenotypes of Δfis1 [33]. However, a role for WHI2 in mitophagy or autophagy is 
controversial. Klionsky and colleagues reported that deletion of whi2 did not affect 
mitophagy, but instead required the fission function of FIS1 when autophagy was 
induced by a classical stimulus nitrogen starvation [42, 43].  
Our lab performed a genome-wide screen to identify knockout strains that grow 
significantly better than wild type on low amino acid medium. The top hit in this screen 
was the knockout of WHI2, and this screen also identified TORC1 negative regulators 
NPR2/3 mentioned above. This same screen for genes required to reduce cell growth in 
low amino acids identified almost all of the components of the ESCRT pathway [34]. The 
ESCRT complexes are a series of 5 complexes, ESCRT-0, ESCRT-I, ESCRT-II, ESCRT-
III, and the vps4 complex (ESCRT-IV), that are important for endosomal trafficking, 
vesicle sorting and other functions [45]. In yeast, they play an integral role in delivering 
cargo to the vacuole, which is also the primary organelle where nutrients are stored and 
cellular components begin degradation [45]. Cierra Sing, a previous masters student in 
our lab, tested and found that a deficiency in ESCRTs leads to a defect in nutrient sensing 
Knockouts of ESCRT complex components results in an overgrowth phenotype similar to 













Figure 1 – TOR complexes in mammalian and yeast cells 
a) mTORC1 in mammalian cell. mTOR is bound with mLST8, DEPTOR, RAPTOR, 
PRAS40, and Tti1/Tel2. b) TORC1 in yeast cell. Tor1 is bound to Lst8, Tco89p, and 
Kog1. c) mTORC2 in mammalian cell. mTOR is bound with Tti1/Tel2, mLST8, 
DEPTOR, and PRAS40 (similar to mTORC1). It is also bound to RICTOR and 
PROTOR. d) TORC2 in yeast cell. Tor2 is bound to Lst8 like TORC1. Tor2 is also 
bound to Avo1, Avo2, Avo3, and Bit61. Figure Adapted from Bar-Peled et al. and Cuyàs 
et al. [2, 7].  




Figure 2  
 
 
Figure 2 – Upstream pathway in amino acid dependent activation of mTORC1 
a) mTORC1 inactivation in low amino acid conditions. RagA/B is GDP bound, and the 
GEF activity of the Ragulator is inhibited by GATOR1, and mTORC1 is not localized to 
the lysosomal membrane. The TSC1/2 complex is still interacting with Rheb, regardless 
of amino acid conditions. SLC38A9.1 is bound to the Ragulator, but not activated. b) 
mTORC1 activation in response to amino acids. GATOR2 inhibits GATOR1, allowing 
the Ragulator to exchange GDP on RagA/B for GTP. GTP-bound RagA/B recruits 
mTORC1 to the lysosomal service, which can be activated by the TSC1/2-Rheb pathway. 
Additionally, high arginine may cause conformational changes SLC38A9.1, which is 
relayed to the Ragulator. Or, the non-membrane associate end may associate with 
RagC/D to localize TOR. The exact function of SLC38A9.1 is still unclear. Figure 
adapted from Bar-Peled et al. and Brown et al. [2, 13]. 
 






Figure 3 – TORC1/mTORC1 downstream pathways 
Upon TORC1/mTORC1 activation different proteins are phosphorylated resulting in the 
changes to cellular processes that increase growth. TORC1 directly phosphorylates Sch9 
and Tap42, which in turn regulate the multiple downstream proteins to regulate amino 
acid synthesis, stress response, autophagy, translation, transcription, and growth. Figure 
adapted from Hughes Hallet et al. [23].  
  






Figure 4 – Alignment of N-terminal end of yeast Whi2 and human KCTDs 
Protein sequence alignment of the N-terminal end of Whi2 from two yeast strains, S. 
cerevisiae and S. pombe, with various human KCTD proteins. The N-terminal end of the 
KCTDs contains the BTB (BR-C, ttk and bab) domain, which is a binding domain highly 







Materials and Methods 
 
Yeast Strains and Media 
All knockout yeast strains used have a BY4741 background with engineered 
auxotrophies (Table 1). The background parental “wild type” strains, unlike wild strains, 
which are prototrophs for all 20 amino acids, were engineered to be auxotrophs for four 
amino acids (histidine, lysine, leucine and methionine) and uracil. Similarly, human cells 
are auxotrophic for phenylalanine, valine, threonine, tryptophan, methionine, leucine, 
isoleucine, lysine, and histidine [46, 47].  
The rich medium YPD [1% yeast extract (Fisher Scientific), 2% peptone 
(Peptone-Y, MP Biomedicals), 2% D-glucose/dextrose (Fisher Scientific)] was used to 
grow all un-transformed strains in preparation for experiments. All SCD media, including 
low amino acid media and amino acid dropout media, contained 0.67% yeast nitrogen 
base without amino acids (BD and Sigma-Aldrich), 0.2% glucose (Fisher Scientific), and 
different combinations of dissolved amino acid solutions (Table 2 and Appendix 1). 
Two sets of media were made independently from dissolved amino acids to confirm the 
results. Amino acids were dissolved in liquid at 1.0 g/100 mL (except cysteine at 0.1 g/10 
mL, aspartic acid at 0.5 g/100 mL, and tyrosine at 0.1 g/100 mL) and sterilized by 
filtration with 0.2µm filter. To reduce potential errors, dropout mixes were commonly 
shared between recipes where possible. YPD and SCD (synthetic complete dextrose) agar 
plates were made by adding 2% agar (BD) to liquid YPD. All media was steamed 




auxotrophic nutrients from the media, selecting against cells that cannot synthesize the 
missing nutrient. There are benefits over drug or other selection and have been well 
documented, such as the lack of protein expression that may cause protein aggregation 
[49]. 
 
Yeast Serial Dilution Plating 
All wild type and knockout yeast strains (Table 1) were streaked from frozen 
15% glycerol stocks without thawing onto YPD agar plates and allowed to incubate at 
30°C for 2 days. Transformed strains were streaked from frozen 15% glycerol stocks 
without thawing onto SCDCSH-URA agar plates and allowed to incubate at 30°C for 2 
days. Single colonies were picked from the plates and inoculated into 3 mL of YPD 
(SCDCSH-URA for transformed cells) and grown overnight (at least 14 hours) at 30°C on 
a rotator. OD600 for each yeast culture was then measured using Thermo Scientific® 
Genesys 10s Vis Spectrophotometer. Overnight cultures were initially diluted to 0.5 
OD600/mL with water to ~100uL total volume, then serially diluted 1:5 5 times with 
water, and 3 µL of the original 0.5 OD600 dilution and 5 serial dilutions were plated onto 
SCDCSH, SCDME, and other plates with the indicated amino acid compositions. The plates 
were incubated at 30°C and images were taken and archived after 3 days of incubation. 
Images shown in the figures presented were 0.05 second exposures taken using a Bio-
Rad® Universal Hood III imaging system and the ImageLab 5.0 software after the 3 day 
incubation. All plates shown are representative images from experiments that have been 




were both increased by 20% each in PowerPoint to increase visibility, unless otherwise 
noted. 
Plasmid Transformation 
Wild type and Δwhi2 strains were transformed with BQ23 (empty vector with 
URA3 selection cassette), TXC19 (BQ23 vector expressing HA-Whi2), or GFP-Atg8 
plasmids using the following established lab protocol. An overnight 3 mL yeast culture in 
YPD (grown at least 14 hours at 30°C on a rotator) was diluted to prepare 2 mL yeast 
cultures of 0.20 OD600/mL in YPD, which were incubated at 30°C for 3-4 hours or until 
the OD600 was between 0.5-1.0 OD/mL. OD600 for each yeast culture was then measured 
using Thermo Scientific® Genesys 10s Vis Spectrophotometer. 1 mL of yeast culture 
was centrifuged using a Sorvall® Biofuge Pico model microcentrifuge at 13,000 RPM 
for 2 minutes; the pellet was washed once with 0.1 M LiAc, and resuspended with 100 
µL of LiAc. 5 µL per transformation of denatured salmon sperm DNA (ssDNA) was 
prepared by boiling at 100°C for 5 minutes and place on ice. 1-2 µg of plasmid DNA, 5 
µL ssDNA and 350 µL of transformation plate mix were added to the resuspended yeast 
cells. The mixture was incubated for 30 minutes 30°C on a rotator. After the incubation, 
the sample was heat shocked for 10 minutes in a 42°C water bath. The samples were 
centrifuged at 13,000 RPM for 2 minutes, resuspended in 100 µL of water, and spread 
onto a selective yeast plate (SCDCSH-URA, Appendix 1). Plates were incubated for 2 days 





Table 1 Yeast strains used in this study 
Strain 
Name Background Genotype Notes 
WTα BY4742 MATα, his3Δ1, leu2Δ0, lys2Δ0, ura3Δ0 
Glycerol stock obtained from Jef 
Boeke lab 
WTa BY4741 MATa, his3Δ1, leu2Δ0, met15Δ0, ura3Δ0 




MATa, his3Δ1, leu2Δ0, 
met15Δ0, ura3Δ1 
Substrain stock made from clean 
KO verified by tetrad analysis done 
previously by Xinchen Teng.  
Δvps4 
ss03_18 BY4741 
MATa, his3Δ1, leu2Δ0, 
met15Δ0, ura3Δ2 
Substrain stock made from clean 
KO verified by tetrad analysis done 
previously by Cierra Sing.  
Δvps27 
ss15_08 BY4741 
MATa, his3Δ1, leu2Δ0, 
met15Δ0, ura3Δ3 
Substrain stock made from clean 
KO verified by tetrad analysis done 
previously by Cierra Sing.  
Δvps28 
ss08_11 BY4741 
MATa, his3Δ1, leu2Δ0, 
met15Δ0, ura3Δ4 
Substrain stock made from clean 
KO verified by tetrad analysis done 
previously by Cierra Sing.  
Δsnf7 
ss01_06 BY4741 
MATa, his3Δ1, leu2Δ0, 
met15Δ0, ura3Δ5 
Substrain stock made from clean 
KO verified by tetrad analysis done 
previously by Cierra Sing.  
Δsnf8 
ss08_14 BY4741 
MATa, his3Δ1, leu2Δ0, 
met15Δ0, ura3Δ6 
Substrain stock made from clean 
KO verified by tetrad analysis done 
previously by Cierra Sing.  










Table 2 Basic SCD recipes (cont.) 
 




Figure 5  
 
 











Our lab performed a cell death screen of yeast knockout strains to identify cell 
death-sensitive/-resistant strains following cell stress. This screen identified Δwhi2 as a 
particularly death-sensitive knockout strain, although both Δwhi2 and wild type strains 
grew indistinguishably prior to a cell death stimulus (on YPD) [33]. Unexpectedly, the 
death-prone Δwhi2 strains grew up to 100-fold better than wild type when plated (without 
treatment) on a low amino acid synthetic complete medium with dextrose (SCD) 
prepared by the recipe published in Methods in Enzymology, therefore designated 
SCDME (Table 2) [50]. This recipe has lower total amino acid levels than the SCD recipe 
published by Cold Spring Harbor Press SCDCSH, where both strains grow 
indistinguishably (Table 2) [33]. This suggested that Δwhi2 mutants fail to sense or 
respond to low amino acids [34]. Therefore, a genome-wide screen of the knockout 
collection (BY4741 background) was performed to identify all the genes in yeast required 
to slow cell growth in low amino acid medium. In this screen, 751 unique knockout 
strains were found to substantially overgrow compared to wild type [34]. This failure to 
arrest growth under low amino acid conditions, as exhibited in Δwhi2 mutant cells, is 




Given that amino acids were known to be a potent activator of mTORC1 and 
TORC1, Wen-Chih Cheng in our lab explored possible involvement of TORC1 [34]. 
Margaret Dayhoff-Brannigan and others in the lab showed that supplementing the SCDME 
media with leucine to 300 mg/L, thereby mimicking the high leucine concentration in 
SCDCSH (367 mg/L, Table 2), could rescue WT growth to match that of Δwhi2 mutants 
[51]. Therefore, leucine was sufficient to restore otherwise restricted growth of wild type 
strains. they also performed the inverse experiment, reducing the leucine in SCDCSH to 
match low levels in SCDME, 30 mg/L. As predicted, Δwhi2 mutants grew better than wild 
type, but curiously, the overall growth for all strains was severely reduced despite having 
higher total amino acid levels [51]. I found this intriguing, as it seemed to indicate that 
the cell growth responded to amino acids other than L-leucine. Therefore, I investigated 




WHI2 and ESCRT complexes are required to respond to low leucine 
Low amino acid medium (SCDME) causes wild type yeast to slow their growth 
[33]. The slow growth is not due to insufficient nutrients because our lab found that 
deletion of WHI2 results in a dramatic overgrowth phenotype. I recapitulated these 
findings, showing that Δwhi2 mutants grow far better than wild type on SCDME (Fig. 6b) 
but not SCDCSH, where wild type and Δwhi2 grow indistinguishably (Fig. 6a). The two 
greatest differences between the two media SCDME and SCDCSH is the total amino acid 




among individual amino acids is the leucine concentration, which is ~10-fold lower in 
SCDME compared to SCDCSH (30 mg/L vs. 367 mg/L, respectively) (Table 2). Given the 
importance of leucine sensing in mammalian cells, we suspected that WHI2 might be 
specifically required to respond to low leucine concentrations. However, a 10-fold 
difference in any other amino acid could potentially have the same effect, as the 
experiments performed thus far did not definitively distinguish between these possible 
explanations. Therefore, I designed and tested a number of different media that differ in 
amino acid content and composition to determine which amino acid(s) specifically 
require yeast WHI2 to appropriately reduce cell growth in the face of nutrient deprivation. 
I analyzed the growth of WT, Δwhi2, and representative knockout strains from different 
ESCRT complexes to achieve this goal, revealing some additional surprising findings. 
The knockout strains used in this project lack Vps27 (found in ESCRT-0), Vps28 (found 
in ESCRT-1), Snf8 (found in yeast ESCRT-II), Snf7 (found in ESCRT-III), or Vps4 
(found in ESCRT-IV) [45]. Note that tetrad analyses were performed on all of these 
strains to verify that the knockout gene itself is responsible for the overgrowth phenotype 
[46]. 
Because the leucine concentration of SCDCSH is exceptionally high compared to 
other amino acids in SCDCSH and when compared to leucine levels in SCDME, and 
because leucine is a known regulator of cell growth we considered that yeast WHI2 is 
required to slow cell growth specifically in low leucine [2]. To investigate this 
possibility, I prepared plates in which all components remained the same except that the 
leucine concentrations were reversed between SCDME and SCDCSH, similar to those in the 




to reflect the amount of leucine in the SCDME plate (30 mg/L Leu), and the concentration 
of leucine in the SCDME plate (30 mg/L) was increased to 367 mg/L. Lowering the 
leucine concentration of SCDCSH revealed an overgrowth phenotype by Δwhi2 and the 
ESCRT knockout strains, although the growth of all strains was unexpected reduced (Fig. 
6c). Conversely, increasing the amount of leucine in the SCDME recipe to 367 mg/L 
abolished the overgrowth phenotype typical of SCDME, and all strains grew similarly and 
robustly (Fig. 6d). These results confirmed previous findings in our lab and implicate 
leucine as a key influence on the Δwhi2 overgrowth phenotype [51]. 
While inverting the leucine concentrations in SCDCSH or SCDME was sufficient to 
affect the overgrowth phenotype of the Δwhi2 and ESCRT knockout strains, changes 
made to leucine concentrations also changed the total concentration of amino acids in 
each recipe. Thus, it was possible that the overgrowth phenotype could be attributed 
simply to the low total amino acid levels, which differed by 561 mg/L, irrespective of any 
specific amino acid. To address this concern, I increased the total amino acids of SCDME 
(1200 mg/L) to 2000 mg/L to approximate (exceed) the total amino acid levels in 
SCDCSH (1761 mg/L) without changing the ratios between individual amino acids in 
SCDME, designated SCDME[Up] (recipe in Appendix 1). However, even though the total 
amino acid concentration was high, a particularly strong overgrowth phenotype was 
observed for Δwhi2 and the ESCRT knockout strains (Fig. 7c). This implies that the 
overgrowth phenotype was not affected by the total amino acid concentrations in these 
experiments. To further rule out effects of total amino acid concentrations as a 
contributing factor in restricting WT and not the Δwhi2 and ESCRT knockout strains, I 




recipe in Table 1), but which has relatively high leucine levels (100 mg/L) [52]. This 
recipe did not result in overgrowth phenotypes (Fig. 7d), despite having ~400 mg/L 
lower total amino acids than SCDME (1200 mg/L). This confirms that the total amino 
acids, at the concentrations tested (between 800 mg/L and 1761 mg/L), do not explain the 
slow growth of wild type relative to these knockout yeast strains. Together these results 
are consistent with leucine being sensed in a ratio with other amino acids. Interestingly, 
the relative amount of leucine in SCDDawes (12.3% of total) is more comparable to 
SCDCSH (20.8% of total), while leucine makes up only 2.5% of the total amino acids in 
SCDME. Thus, the percent of leucine was important while the absolute amount was not.  
The results thus far are consistent with the possibility that either a low leucine 
threshold exists or that a ratio between leucine and other amino acids in the media 
regulate the overgrowth phenotype. To address the possibility that the overgrowth 
phenotype is due to the leucine concentration falling below a threshold, I titrated the 
leucine concentration in SCDCSH and SCDME recipes. On modified SCDCSH plates, when 
the leucine concentration dropped below 60 mg/L and the percent of leucine dropped 
below 4% of the total amino acid concentration, the overgrowth phenotype returned (Fig. 
8a-d; recipes in Appendix 1). Conversely, increasing the leucine concentration in 
SCDME from 30 mg/L to 50 mg/L (4% Leu) or more abolished the overgrowth phenotype 
(Fig. 8e-g). This suggests that rather than the absolute concentration of leucine being the 
threshold restricting WT strain growth, the overgrowth phenotype occurs when the 
percent of leucine compared to the total amino acid concentration drops below 4%. This 
idea is further supported when comparing SCDME[Up] (48 mg/L, 2% Leu) (Fig. 9c) with 




concentrations but different leucine contributions to total amino acid concentration. This 
is consistent with the threshold of the leucine concentration being 4% of the total amino 
acid concentration. While not related to the overgrowth phenotype, a drastic increase in 
overall growth was observed between the SCDCSH media with 30 mg/L of leucine and the 
one with 40 mg/L of leucine. As an auxotrophic amino acid, it may be possible that there 
is a minimum threshold of leucine concentration required to sustain growth. However, 
this seems to indicate that there is a relatively narrow range in which the leucine 








Figure 6 – Low leucine restricts growth in the WT strains, but not the Δwhi2 or 
ESCRT complex KO strains 
(a) Representative growth of WT, Δwhi2 and ESCRT knockout strains on high amino 
acid (SCDCSH) medium. All strains grew well at all dilutions. (b) Representative growth 
of WT, Δwhi2 and ESCRT KO strains on low amino acid (SCDME) medium. For WT 
strains, growth is observed only for the first few dilutions in the series, while growth is 
observed for all dilution factors for the Δwhi2 and ESCRT KO strains. (c) Representative 
growth of WT, Δwhi2 and ESCRT KO strains on SCDCSH with ME levels of leucine. For 
all strains, growth is reduced, although Δwhi2 and ESCRT KO strains retain an 
overgrowth phenotype relative to wild type. (d) Representative growth of WT, Δwhi2 and 
ESCRT KO strains on SCDME with high leucine levels. All strains grew well at all 
dilution factors.  
Strains were grown in preparation for dilution according to protocol outlined 
above. All strains were diluted and plated at the same time. Contrast increased by 20% 
and brightness increased by 40% for plate (c) to improve visibility. Shown is a 








Figure 7 – Overgrowth by Δwhi2 and ESCRT complex KO strains not dependent on 
total amino acid concentrations 
(a) Representative growth of WT, Δwhi2 and ESCRT KO strains on SCDCSH medium. 
All strains grew well at all dilution factors. (b) Representative growth of WT, Δwhi2 and 
ESCRT KO strains on published SCDME medium. WT strains exhibited growth only for 
the first few dilutions in the series, while growth is observed for all dilution factors for 
the Δwhi2 and ESCRT KO strains. (c) Representative growth of WT, Δwhi2 and ESCRT 
KO strains on SCDME medium with proportionately higher levels (~1.6? fold) of all 
amino acid components (2000 mg/L) The growth phenotype of the WT, Δwhi2 and 
ESCRT KO on this media reflected SCDME. d) Representative growth of WT, Δwhi2 and 
ESCRT KO strains on another established low amino acid, but moderate leucine 
concentration, (SCDDawes) media. All strains grew well at all dilution factors.  
Strains were grown in preparation for dilution according to protocol outlined 
above. All strains were diluted and plated at the same time. Shown is a representative of 





Figure 8 – Leucine contribution of less than 4% by weight to total amino acid 
concentration may act as threshold of overgrowth phenotype 
(a-h) Representative growth of WT, Δwhi2 and ESCRT KO strains on SCD media with 
varying leucine concentrations as indicated. In (a-c), the WT strains did not grow at all 
dilution factors, but showed better growth with higher leucine concentrations, while the 
Δwhi2 and ESCRT KO strains grew well at all dilutions. In (d), all strains grew well at all 
dilution factors. (e-h) Representative growth of WT, Δwhi2 and ESCRT KO strains 
SCDME media with the indicated leucine concentrations. For any amount of added leucine 
to SCDME, growth was observed at all dilution factors for the WT, Δwhi2 and ESCRT 
KO strains; no overgrowth phenotypes observed.   
Strains were grown in preparation for dilution according to protocol outlined 
above. All strains for plates (a)-(d) were diluted and plated at the same time, and all 
strains for plates (e)-(g) were plated at the same time. Contrast and brightness increased 
by 40% on plate (a) to improve visibility. Shown is a representative of 3 independent 












Figure 9  
 
Figure 9 – Low leucine ratio to other amino acids restricts WT growth but not for 
Δwhi2 and ESCRT KO strains 
(a-c) These are the same panels as Fig. 7(a-c) included here for comparison. (d) This is 
reproduced from Fig. 8e. Representative growth of WT, Δwhi2 and ESCRT KO strains 
on modified SCDME medium except with slightly higher leucine concentration compared 
to (c). In contrast to (b) and (c), all strains grew well at all dilution factors in (d).  
Strains were grown in preparation for dilution according to protocol outlined 
above. All strains for plates (a)-(c) were diluted and plated at the same time, plate (d) was 
plated separately. Shown is a representative of at least 3 independent experiments using 




Other amino acids play a role in regulating growth in low leucine 
With the data above suggesting that a specific leucine threshold exists, I wanted to 
determine if the overgrowth phenotype could be recapitulated in any media comprised of 
less than 4% by weight of leucine, supporting the hypothesis above that a low leucine 
environment was determined by less than 4% of leucine contributing to the total amino 
concentration. To test this, I developed and tested two new low amino acid recipes for 
overgrowth phenotypes. The first recipe, SCDMEDD, was based on a combination of 
SCDME and SCDDawes, designated SCDMEDD (MEDD – ME and Dawes Derived), which 
has 570 mg/L total amino acids and the same 30 mg/L leucine concentration as SCDME 
(5.26% Leu). SCDMEDD resulted in low growth of the WT strains and overgrowth of the 
ESCRT knockout strains, but interestingly, unlike SCDME, the Δwhi2 strain showed WT-
like depressed growth (Fig. 10c). This dichotomy of Δwhi2 overgrowth is explored 
further in below. However, SCDMEDD had a leucine to total amino acid concentration 
ratio higher than the 4% threshold suggested above, yet exhibited an overgrowth 
phenotype in the ESCRT knockout strains. This disproves the idea that a threshold of 
leucine to total amino acid ratio resulted in the overgrowth phenotype, and rather 
encourages the idea that some ratio between leucine and certain, but not all, amino acids 
in the recipes was important.   
 In the second new recipe, SCDAux, the total amino acid level was reduced even 
further to 90 mg/L (Table 2) and contains only the four auxotrophic amino acids required 
to sustain viability. SCDAux has the same leucine concentration as SCDME of 30 mg/L, but 
accounts for 33.3% of the total amino acids. The uniform and surprisingly strong growth 




that neither the low total amino acid concentration nor low absolute leucine 
concentrations is solely responsible (Fig. 10d). As predicted, leucine’s 33.3% 
contribution by weight to total amino acid is above the 4% threshold suggested earlier 
resulting in no overgrowth phenotype. As this recipe only contained the essential amino 
acids yet supported robust growth, it was a good system to test whether adjusting the 
contribution of leucine to the total amino acid concentration could recover the 
overgrowth phenotype without the potential interference from other amino acids.  Even 
when keeping leucine constant at 30 mg/L and titrating the other auxotrophic amino acids 
(histidine, lysine and methionine), such that leucine was 2.5% (SCDAux[2.5% Leu], recipe 
in Appendix 1) of the total amino acids, the overgrowth phenotype was not restored (Fig. 
11d-f). The overgrowth phenotype on SCDMEDD (5.26% leucine by weight of total amino 
acids) and the lack of overgrowth on the modified SCDAux[2.5% Leu] refute the 
hypothesis made earlier that the percent of leucine in the total amino acid concentration 
plays a role in the overgrowth phenotype.  
These results imply that the overgrowth phenotype is not due to simply the 
percent of leucine in the total amino acid concentration. As mentioned earlier, the second 
possibility is that there is a relationship between leucine and a subset of other amino acids 
that may be the cause of the overgrowth phenotype. This idea is supported by the 
research done by Sabatini’s group showing that mammalian cell growth in response to 
leucine requires the presence of other amino acids [2]. One amino acid of particular 
interest is methionine because evidence implicates low methionine concentrations 
prolong survival in yeast models and mammalian tumor models [52, 53]. Additionally 




Met) or SCDCSH (73.4 mg/L Met). The low methionine concentrations in the SCDAux 
media raised the possibility that the lack overgrowth phenotype on SCDAux may be a 
result of the methionine concentration affecting survival, as reported in the literature. To 
test whether the reported methionine restriction increased survival would manifest as 
overgrowth of the Δwhi2 and ESCRT KO strains compared to WT strains, I reduced the 
methionine concentration of SCDAux to 10 mg/L and also increased it to 100 mg/L. 
However, my results indicate that increasing methionine to 100 mg/L did not reveal the 
overgrowth phenotype (Fig. 12d). In contrast to the better survival of yeast in low 
methionine reported in the literature [52, 53], decreasing methionine in SCDAUX to 10 
mg/L did not improve growth or survival on the plates, but rather decreased overall 
growth for all strains (Fig. 12c). Such decrease in overall growth could be explained by 
insufficient methionine, as the lowest methionine concentration used in the literature for 
methionine restriction is 30 mg/L, even though the SCDME, SCDDawes, SCDAux, and 
SCDMEDD recipes already only contain 20 mg/L [53]. The inability to recover the 
overgrowth phenotype when increasing the auxotrophic amino acids together (Fig. 11d-f) 
or methionine individually (Fig. 12c-d) in SCDAUX suggests that these auxotrophic amino 
acids are not sensed in combination with leucine to restrict WT growth that result in the 
overgrowth phenotype. 
The findings suggest that the ratio of leucine to histidine, lysine or methionine are 
not the individual or in combination the cause of overgrowth phenotype. As the 
auxotrophic amino acid concentrations between SCDAux (20 mg/L His, Lys, Met and 30 
mg/L Leu) and SCDMEDD (20 mg/L His, Met and 30 mg/L Lys, Leu) are extremely 




phenylalanine, threonine, tryptophan, tyrosine, and valine, as well as the purine 
derivative, adenine, which are the remaining amino acids that would account for the 
overgrowth phenotype on SCDMEDD that is not present on SCDAux. To determine which of 
these amino acids can rescue the overgrowth phenotype, each amino acid was 
individually added to SCDAux at the same concentrations present in SCDMEDD. However, 
adding back the amino acids or adenine individually did not rescue the overgrowth 
phenotype (Fig. 13a-h). These results indicate that a single amino acid addition is not 
sufficient to rescue the overgrowth phenotype on SCDAux, which implies that a group of 
amino acids are required to restrict growth in the low leucine of SCDAux. This idea is not 
novel, as studies in S. cerevisiae have shown that specific amino acids are considered 
“high-end” nitrogen sources, which promote growth, while others were considered “low-
end” nitrogen sources, which have no positive effect on growth [55]. I also tested the 
following combinations of amino acids added to SCDAux: arginine, asparagine, valine, 
and threonine; isoleucine, phenylalanine, tryptophan, and tyrosine; valine, tryptophan, 
and tyrosine; arginine, asparagine, isoleucine, phenylalanine, and threonine; arginine, 
asparagine, tryptophan, and tyrosine; isoleucine, phenylalanine, and valine; and lastly, 
tryptophan, threonine, and tyrosine (recipes in Appendix 1). However, none of these 
combinations resulted in the restriction of WT growth and overgrowth of the Δwhi2 or 
ESCRT knockout strains (Fig 14a-g). As not all possible amino acid combinations have 
been tested, and the classification of “high-end” and “low-end” nitrogen sources were not 







Figure 10 – Leucine is sensed in a ratio with other amino acids even at low 
concentrations 
(a) Representative growth of WT, Δwhi2 and ESCRT KO strains on rich (SCDCSH) 
media. All strains grew well at all dilution factors. (b) Representative growth of WT, 
Δwhi2 and ESCRT KO strains on SCDME medium. For WT strains, growth is observed 
only for the first few dilutions in the series, while growth is observed for all dilution 
factors for the Δwhi2 and ESCRT KO strains. (c) Representative growth of WT, Δwhi2 
and ESCRT KO strains on SCDMEDD medium. For WT and Δwhi2 strains, growth is 
faintly observed only for the first few dilutions in the series, while growth is observed for 
all dilutions factors for the ESCRT KO strains. By visual comparison of spot density, 
overall growth on SCDMEDD is slightly poorer than SCDME. (d) Representative growth of 
WT, Δwhi2 and ESCRT KO strains on medium containing only the 4 auxotrophic amino 
acids, SCDAux. All strains grew well at all dilution factors. By visual comparison of spot 
density, overall growth is slightly worse than SCDCSH. 
Strains were grown in preparation for dilution according to protocol outlined 
above. All strains were diluted and plated at the same time. Shown is a representative of 




Figure 11 – Leucine concentration independent of other amino acids, does not 
account for overgrowth phenotype 
a) Representative growth of WT, Δwhi2 and ESCRT KO strains on rich (SCDCSH) media. 
All strains grew well at all dilution factors. b) Representative growth of WT, Δwhi2 and 
ESCRT KO strains on pre-established low nutrient (SCDME) media. For WT strains, 
growth is observed only for the first few dilutions in the series, while growth is observed 
for all dilution factors for the Δwhi2 and ESCRT KO strains. c) Representative growth of 
WT, Δwhi2 and ESCRT KO strains on SCDAux. All strains grew well at all dilution 
factors. By visual comparison of spot density, overall growth is slightly worse than 
SCDCSH. d-f) Representative growth of WT, Δwhi2 and ESCRT KO strains when 
varying amino acids aside from leucine in the auxotrophic amino acid media (SCDAux). 
Varying the other amino acids while keeping leucine constant did not result in the 
recovery of the overgrowth phenotype. 
Strains were grown in preparation for dilution according to protocol outlined 
above. All strains were diluted and plated at the same time. Shown is a representative of 













Figure 12 – Overgrowth phenotype by whi2 and ESCRT mutants is not due to 
leucine being an auxotrophic amino acid   
(a) Representative growth of WT, Δwhi2 and ESCRT KO strains on SCDCSH medium. 
All strains grew well at all dilution factors. (b) Representative growth of WT, Δwhi2 and 
ESCRT KO strains on SCDME media. For WT strains, growth is observed only for the 
first few dilutions in the series, while growth is observed for all dilution factors for the 
Δwhi2 and ESCRT KO strains. (c-d) Representative growth of WT, Δwhi2 and ESCRT 
KO strains when varying methionine concentrations in the context of the auxotrophic 
amino acid media SCDAux. Due to the requirement for methionine, decreasing methionine 
to 10 mg/L resulted in stunted overall growth for all strains in (c). The poor growth made 
differentiating growth phenotype impossible, and so it is unknown if an overgrowth was 
present. (d) Increasing the amount of methionine did not change the growth phenotype 
for any of the strains. 
Strains were grown in preparation for dilution according to protocol outlined 
above. All strains were diluted and plated at the same time. Contrast and brightness were 
increased by 40% for plate (c) to improve visibility. Shown is a representative of at least 






Figure 13 – Low leucine overgrowth phenotype for the Δwhi2 or ESCRT complex 
KO strain requires more than leucine and a single amino acid addition 
(b-h) Representative growth of WT, Δwhi2 and ESCRT KO strains on modified SCDAux, 
where arginine (b), aspartic acid (c), isoleucine (d), phenylalanine (e), threonine (f), 
tryptophan (g), or valine (h) were individually added to SCDAux to reflect SCDMEDD 
levels. Regardless of the individual amino acid added, the WT, Δwhi2 and ESCRT KO 
strains grew well at all dilution factors. 
Strains were grown in preparation for dilution according to protocol outlined 
above. All strains were diluted and plated at the same time. Shown is a representative of 3 








Figure 14 – Adding back combinations of amino acids have yet to reveal overgrowth 
phenotype on SCDAux 
(a-g) Representative growth of WT, Δwhi2 and ESCRT KO strains on modified SCDAux 
where combinations of amino acids were added to SCDMEDD levels. Combinations of 
amino acids were randomly determined. No overgrowth of the Δwhi2 and ESCRT KO 
strains was observed for any combination tested. (g) Δvps4 showed reduced growth. 
Strains were grown in preparation for dilution according to protocol outlined 
above. Strains for plates (a), (c), (d), (f) were diluted and plated on the same day, and 
strains for (b), (e), (g) were diluted and plated on the same day. Contrast increased by 
20% and brightness increased by 40% for plate (b) to improve visibility. Shown is a 









The restricted growth of the Δwhi2 strain on the SCDMEDD plate compared to on 
SCDME provides a strategy to explore the role that WHI2 plays in restricting growth in 
low leucine environments. Discovering the differences between SCDMEDD and SCDME 
that rescue the overgrowth phenotype in the Δwhi2 strain could provide insight into the 
function that WHI2 plays in nutrient sensing in low leucine environments. 
The biggest difference between SCDMEDD and SCDME is the lack of serine and 
glutamic acid in SCDMEDD, but there are also a lower concentrations of threonine (100 
mg/L in SCDMEDD, 200 mg/L in SCDME), aspartic acid (80 mg/L in SCDMEDD, 100 mg/L 
in SCDME), and valine (140 mg/L in SCDMEDD, 150 mg/L in SCDME) (recipe in Table 2). 
To elucidate which of these amino acids differences contribute to the Δwhi2 overgrowth 
observed in SCDME, the amino acids were added to SCDMEDD to restore SCDME levels to 
assess their effect on the Δwhi2 growth. When restoring all five amino acid differences 
(Fig. 15c) or even the three amino acids with the largest concentration difference (serine, 
threonine, and glutamic acid) (Fig. 15d) to the SCDMEDD media, Δwhi2 strain restored the 
overgrowth phenotype on SCDME. This indicates that serine, threonine, and glutamic 
acid, either together or independently, can restore the overgrowth of the Δwhi2 strain in 




of any one of the three amino acids sufficient to rescue the Δwhi2 overgrowth, each was 
tested separately in SCDMEDD (recipe in Table 2). When testing these amino acids 
individually, glutamic acid was necessary and sufficient to rescue the phenotype (Fig. 
15e), while adding back threonine or serine individually did not rescue the Δwhi2 
overgrowth (Fig. 16g, 16h). 100 mg/L of the remaining 6 amino acids not present in 
either SCDMEDD or SCDME (alanine, asparagine, cysteine, glycine, glutamine, and 
proline) were also individually added to SCDMEDD to determine whether glutamic acid is 
unique in rescuing the Δwhi2 strain overgrowth. However, none of the amino acids tested 
displayed the same ability as glutamic acid in rescuing the Δwhi2 strain overgrowth (Fig. 
16a-f). 
The addition of glutamic acid to SCDMEDD led to changes in the recipe, e.g. the 
total amino acid concentration or pH of media, that needed to be further addressed. To 
address the changes in total amino acid concentration, I increased the total amino acids of 
SCDMEDD (570 mg/L) to reflect SCDMEDD[Glu(100)] (670 mg/L) without changing the 
ratio between each amino acid in SCDMEDD. However, this modified SCDMEDD recipe 
(SCDMEDD[670 tot]) with higher total amino acid concentration did not affect the Δwhi2 
strain growth on SCDMEDD (Fig. 17c). The lack of effect that the higher total amino acid 
had in Δwhi2 overgrowth phenotype was reconfirmed when testing the effect of alanine, 
asparagine, cysteine, glycine, glutamine, and proline on SCDMEDD, which all also had a 
670 mg/L total amino concentration (Fig. 16a-f). To rule out the possibility that acidity 
was a growth stimulant in the Δwhi2 strain, 100 mg/L of aspartic acid was added to 
SCDMEDD media to reflect the amount of glutamic acid added to SCDMEDD[Glu(100)]. 




phenotype (Fig. 17d), indicating that glutamic acid is affecting Δwhi2 growth impendent 
of its acidic characteristics.  
As leucine has been shown earlier to play a role in the overgrowth phenotype, 
100 mg/L leucine was added to SCDMEDD to test whether leucine would affect Δwhi2 
growth on SCDMEDD. While increasing leucine rescued Δwhi2 growth (Fig. 17e), the 
growth of the WT and ESCRT KO strains reflected SCDCSH, suggesting the overgrowth 
phenotype on SCDMEDD[Glu(100)] was abolished by adding additional leucine. 
While glutamic acid was identified as being necessary and sufficient in rescuing 
Δwhi2 overgrowth in low leucine, there is the possibility that this is not a WHI2-specific 
effect. This is especially true due to the possibility of secondary mutations may arise in a 
gene KO strain, but is unlikely in this circumstance as the substrain used had been 
verified to lack secondary mutations [34]. However, to verify that the Δwhi2 overgrowth 
on SCDMEDD[Glu(100)] and SCDME is WHI2 specific, a plasmid encoding HA-Whi2 
regulated by a constitutive promoter (PGK promoter) was transformed into a Δwhi2 
strain and grown on SCDMEDD[Glu(100)] and SCDME. The whi2-rescued strain grew 
similarly to the WT strains transformed with empty vectors, on SCDME and 
SCDMEDD[Glu(100)] (Fig. 19c, 19d). This indicates that WHI2 plays an important role in 
sensing the low leucine environment of SCDME and SCDMEDD. However, this further 
implies a role of WHI2 in a glutamate pathway, which may be important in regulating 





Figure 15 – WHI2 but not most ESCRTs are required to respond to low levels of the 
non-essential glutamic acid 
(a) Representative growth of WT, Δwhi2 and ESCRT KO strains on SCDMEDD. For WT 
and Δwhi2 strains, growth is faintly observed only for the first few dilutions in the series, 
while growth is observed for all dilution factors for the ESCRT KO strains. (b) 
Representative growth of WT, Δwhi2 and ESCRT KO strains on pre-established low 
nutrient (SCDME) media. For WT strains, growth is observed only for the first few 
dilutions in the series, while growth is observed for all dilution factors for the Δwhi2 and 
ESCRT KO strains. (b) Representative growth of WT, Δwhi2 and ESCRT KO strains on 
SCDMEDD with amino acids added back so SCDMEDD to reflect SCDME. The growth 
phenotype reflected that observed on SCDME; growth of WT strains is observed only for 
the first few dilutions in the series, while growth is observed for most dilution factors for 
the Δwhi2 and Δvps4 strains, and for all dilution factors for the remaining ESCRT KO 
strains. Amino acids in (c) and (d) appear to suppress growth compared to (e). (e) 
Representative growth of WT, Δwhi2 and ESCRT KO strains on SCDMEDD with glutamic 
acid added back to reflect SCDME levels. The growth phenotype reflected that observed 
on SCDME; growth of WT strains is observed only for the first few dilutions in the series, 
while growth is observed for most dilution factors for the Δwhi2 and Δvps4 strains, and 
for all dilution factors for the remaining ESCRT KO strains.  
Strains were grown in preparation for dilution according to protocol outlined 
above. Strains for plates (a)-(d) were diluted and plated at the same time. Shown is a 












Figure 16 – Glutamic acid is the only amino acid that has an effect on the difference 
in Δwhi2 overgrowth between SCDME and SCDMEDD 
(a-h) Representative growth of WT, Δwhi2 and ESCRT KO strains on modified 
SCDMEDD media, where 100 mg/L of individual amino acids not present in SCDMEDD 
were added back. Growth phenotypes reflected SCDMEDD regardless of any single amino 
acid added. The ESCRT KOs showed growth for all dilution factors, while the WT and 
Δwhi2 strains only showed weak growth at the first dilution factors. In (e) and (f), glycine 
and proline appear to result very slight improvement of growth in Δwhi2 compared to 
WT. This may be attributable to growth from breakthrough colonies. 
Strains were grown in preparation for dilution according to protocol outlined 
above. All strains for plates (a), (b) and (e)-(h) were diluted and plated at the same time. 
Strains for (c) and (d) were diluted and plated at separate times from each other and the 
rest of the plates. Contrast increased by 20% and brightness increased by 40% for plate 
(c) to improve visibility. Shown is a representative of 3 independent experiments using 











Figure 17 – Other changes to SCDMEDD when adding glutamic acid does not rescue 
Δwhi2 overgrowth 
(a) Representative growth of WT, Δwhi2 and ESCRT KO strains on SCDMEDD. For WT 
and Δwhi2 strains, growth is faintly observed only for the first few dilutions in the series, 
while growth is observed for all dilutions factors for the ESCRT KO strains. (b) 
Representative growth of WT, Δwhi2 and ESCRT KO strains on SCDMEDD with 100 
mg/L added glutamic acid. WT, Δwhi2 and ESCRT KO growth represented SCDME; the 
Δwhi2 and ESCRT KO strains had an overgrowth phenotype compared to WT. (c) 
Representative growth of WT, Δwhi2 and ESCRT KO strains on modified SCDMEDD that 
retained the same relative concentrations of amino acids, but increased the total amino 
acids to 670 mg/L. Growth for all strains reflected what was observed on SCDMEDD. (d) 
Representative growth of WT, Δwhi2 and ESCRT KO strains on modified SCDMEDD, 
where 100 mg/L of aspartic acid was added. Growth for all strains reflected what was 
observed on SCDMEDD. (e) Representative growth of WT, Δwhi2 and ESCRT KO strains 
on SCDMEDD with added leucine. WT, Δwhi2 and ESCRT KO strains all showed growth 
for every dilution factor.  
Strains were grown in preparation for dilution according to protocol outlined 
above.   All strains were diluted and plated at the same time except for plate (c). Shown is 












Figure 18  
 
Figure 18 – WHI2 complementation in the Δwhi2 strain restores WT-like growth 
phenotype in low leucine conditions 
Δwhi2 was transformed with TXC19, a plasmid containing constitutively expressed HA-
Whi2. The WT and ESCRT KO strains were transformed with BQ23, an empty vector 
with the same selection marker as TXC19. Protocol can be found in text.  
(a) Representative growth of transformed WT, Δwhi2 and ESCRT KO strains on 
SCDCSH medium. All strains grew well at all dilution factors. (b) Representative growth 
of transformed WT, Δwhi2 and ESCRT KO strains on SCDME media. For WT strains and 
the complemented Δwhi2 strain, growth is observed only for the first few dilutions in the 
series, while growth is observed for all dilution factors for the ESCRT KO strains. 
Complementation of whi2 abolished the overgrowth observed in 6(b). (c) Representative 
growth of transformed WT, Δwhi2 and ESCRT KO strains on SCDMEDD. For transformed 
WT strains and complemented Δwhi2, growth is faintly observed only for the first few 
dilutions in the series, while growth is observed for all dilution factors for the ESCRT 
KO strains. (d) Representative growth of transformed WT, Δwhi2 and ESCRT KO strains 
on SCDMEDD with added glutamic acid. For transformed WT strains and complemented 
Δwhi2, growth is observed only for the first few dilutions in the series, while growth is 
observed for all dilution factors for the ESCRT KO strains. Complementation of whi2 
abolished the overgrowth observed in 15(e).  
Strains were grown in preparation for dilution according to protocol outlined 
above. All strains were diluted and plated at the same time. Contrast increased by 20% 
and brightness increased by 40% for plate (b), (c), (d) to improve visibility.  Shown is a 





Discussion Of Results and Future Directions 
 
Discussion of Results 
Utilizing different amino acid conditions revealed two significant conclusions 
about the Δwhi2 overgrowth phenotype observed for a number of yeast knockout strains 
in specific low nutrient conditions. First, it was identified that leucine is an important 
amino acid in regulating growth, which is not appropriately regulated in low leucine 
conditions without the ESCRT complex or WHI2. It was further shown that other amino 
acids are required to restrict WT growth in low leucine, implying that other amino acids 
are sensed along with leucine to regulate cellular growth. Additionally, it was shown that 
glutamic acid is the only amino acid that can rescue the overgrowth of the Δwhi2 strain 
on SCDMEDD, implying that WHI2 may play a role in glutamic acid synthesis in stress 
conditions. Lastly, the growth of the Δwhi2 strain on SCDMEDD and SCDME was restored 
to WT levels after transformation with HA-Whi2, indicating that WHI2 plays a 
significant role in regulating cellular growth. 
It is interesting to note that the many different SCD recipes are utilized in the field 
and most papers do not specify the exact components. While certain recipes, such as 
SCDCSH, SCDME, and SCDDawes, are more commonly used, they are not well 
characterized or classified. It becomes more convoluted as different groups make 
modifications to the recipes to suit the amino acid(s) they are investigating. With my 




growth, the results obtained when changing media components may not be strictly 
indicative of the effect of a single amino acid, but rather a subset of amino acid 
interactions. However, without knowing which amino acids are sensed together, much 
more needs to be done before the effects of different SCD recipes can be understood. 
While I showed that other amino acids play an important role in restricting growth 
in response to low leucine, it remains unclear specifically which amino acids have this 
function. One aspect yet to be tested is the contribution of these amino acids to the 
metabolizable food source, not just as signaling molecules. The Hall group showed in S. 
cerevisiae that “high-end” amino acids arginine, asparagine, and glutamine had a potent 
positive effect on S6 phosphorylation, while serine, threonine, isoleucine, leucine, valine, 
aspartate, glutamate, alanine, methionine, phenylalanine, and tryptophan individually 
resulted in rapid depression of S6 phosphorylation, and were designated “low-end” amino 
acids [55].  This is corroborated by some of the amino acid additions to the different SCD 
media that I have tested here, such as slightly depressed overall growth was observed 
after supplementing SCDMEDD with serine (Fig. 15g). One possibility to consider could 
be the balance of “high-end” or “low-end” amino acids with leucine. For example, an 
inadequate amount of “high-end” amino acids or excessive “low-end” amino acids 
relative to leucine could result in the unfavorable growth condition that is not sensed by 
Δwhi2 and ESCRT knockout strains. However, one caveat to the data provided by the 
Hall group in classification of some amino acids, especially leucine, as “low-end”, when 
it has been shown in our S. cerevisiae model and in mammalian cells to have a potent 
positive effect on growth. One of the reasons for this contradiction could be due to the 




not seem to be present in the yeast model the Hall group uses. While the idea between a 
balance of “high-end” and “low-end” amino acids needs to be tested, it would be 
beneficial to reclassify the “high-end” and “low-end” amino acids according to Hall and 
colleagues for our S. cerevisiae model. 
The Huang group reported that ratios between sets of amino acids regulates 
growth, consistent with my findings that ,The Huang group also reported findings 
supporting the idea that ratios between sets of amino acids regulates growth [56].  Using 
the same S. cerevisiae, the group showed that the ratio between the auxotrophic amino 
acids, histidine, leucine, and lysine, and the non-auxotrophic amino acids greatly affected 
the chronological lifespan of yeast [56]. Additionally, this study concluded that glutamic 
acid in extended the lifespan of S. cerevisiae, which they attributed to the enhancement of 
ROS (reactive oxygen species) stress resistance [57]. In a glutamate dehydrogenase 
knockout model, glutamate addition was shown to suppress the production of ROS [57]. 
My observation that the unique ability for glutamic acid to rescue overgrowth of 
the Δwhi2 strain in low leucine condition has opened questions about the role of WHI2 in 
cell growth control. However, little is known roles of glutamic acid in cellular growth or 
function. One possible mechanism through which glutamic acid regulates cellular 
function is as a signaling molecule in its ionized form, glutamate. In neurons, glutamate 
binds to the excitatory receptors, alpha-amino-3- hydroxy-5-methyl-4-isoxazolepropionic 
acid (AMPA)/kainate and N-methyl-D-aspartate (NMDA), and results in in the opening 
of ion channels, specifically for K+, Ca+, and Na+ [58]. Glutamate signaling to these 
receptors can lead to increased depolarization and neuronal activity, which may play a 




can also be metabolized to GABA (gamma-amino-butyrate), the predominant inhibitory 
neurotransmitter commonly associated with epilepsy [59]. Mutations in the KCTD 
proteins, the human homologue of yeast Whi2, have been shown to cause myoclonic 
epilepsy, this link between glutamic acid and WHI2 via neuronal signaling is particularly 
interesting [60], [61]. While there have been GABA transporters found in S. cerevisiae, 
they appear to play different roles than mammalian GABA receptors [59]. In budding 
yeast, GABA has been shown to regulate nitrogen catabolism and may protect yeast 
against oxidative stress [59]. However, a role for glutamic acid acting as a cell-to-cell 
signaling molecule in yeast remains an open possibility. 
Another possibility is that WHI2 plays a role in the conversion of glutamic acid to 
α-ketoglutarate [54, 55]. This process occurs through oxidative deamination of glutamate, 
the ionic form of glutamic acid, by GDH (glutamate dehydrogenase) [63]. Aside from 
being a basic building block for amino acid synthesis, α-ketoglutarate is also an important 
substrate of oxidative production of ATP [24, 62]. With a lack of α-ketoglutarate, the cell 
cannot properly complete the citric acid cycle to produce ATP, which may stall cellular 
growth. This is consistent with findings showing that mutations in whi2 have resulted in 
slightly dysfunctional mitochondria due to improper regulation of mitophagy [27]. 
Dysfunctional mitochondria would result in impaired oxidative respiration, which could 
also be the result of the inability to properly synthesize α-ketoglutarate and undergo the 
citric acid cycle. While this may be a possibility, the inability of glutamine to rescue the 
overgrowth phenotype appears to indicate otherwise. One of the primary sources of 
intracellular glutamate is from processing glutamine by PDG (phosphate-dependent 




precursor for glutamate may indicate the necessity of WHI2 in processing glutamine into 
glutamic acid, or that the effects of glutamic acid are independent of glutamine and the α-
ketoglutarate synthetic pathway. Currently, it is not clear how glutamic acid is regulating 
growth, but elucidating the relationship between glutamic acid and WHI2 could provide 
important information into the mechanisms behind how amino acids and WHI2 regulate 
growth. However, my findings suggest novel roles for glutamic acid in cellular growth 
and function. 
One difficulty when exploring which amino acids play a role in regulating growth 
was the requirement of maintaining the same total concentration of all amino acids, while 
varying the concentration of a single amino acid and the relative concentrations between 
the amino acids could all potentially play a role. As it is impossible to keep the other two 
conditions constant when varying a single amino acid, some of the effects on growth may 
not be entirely due to an addition of the amino acid. For example, increasing leucine to 50 
mg/L in SCDME (1200 mg/L total amino acid concentration), also changes the total amino 
acid concentration to 1220 mg/L, as well as the ratio of leucine to the other amino acids 
in the recipe (e.g. 30 mg/L Leu to 20 mg/L Met in SCDME while 50 mg/L Leu to 20 mg/L 
Met in SCDME[Leu(50)]). The data presented has shown that, separately, total amino acid 
concentration or concentration of an individual amino does not appear to have an effect 
on the overgrowth observed in the Δwhi2 and ESCRT knockout strains. However, it 
would be impossible to test the effect of only changing one amino acid without it 
affecting the total amino acid concentration or its ratio with other amino acid, making a 




Another issue that these experiments were not fully able to address is the 
signaling effect of amino acids on growth versus the need for amino acids as a nitrogen 
nutrient source. Especially when using plates, it is also hard to differentiate between slow 
growth and death on the plate. While microscopy was used to determine small colony 
formation was present at all dilutions (data not shown), it does not rule out the possibility 
that amino acids are affecting a death pathway rather than, or in combination with, a 
growth pathway.  
The dichotomy between the short-term growth and long-term growth of the WT 
and Δwhi2 strains touches on the issue mentioned above. Although the Δwhi2 strains 
clearly grow better than the WT strains on SCDME and SCDMEDD[Glu(100)] plates, the 
OD600 values (data not shown) elucidate poorer growth of the Δwhi2 strains in the liquid 
culture for these media. This phenomenon could be due to the rapid influx of nutrients 
when switching media, even to fresh nutrient-limited media, which drives short-term 
growth. Another potential explanation could be that there are different mechanisms that 
regulate long-term growth. However, one confounding issue is the possibility of 
breakthrough colonies forming in liquid culture. Breakthrough colonies can be 
distinguished on agar plates as colonies that have distinctly better growth than the 
surrounding background, possibly arising due to mutations derived from the selective 
pressure of nutrient stress. While it is easy to visualize on the plates, it would be very 
difficult to tell if the growth in liquid culture was due to a breakthrough colony 







This work provides important groundwork for further projects to not only explore 
nutrient signaling and sensing, but also the roles of WHI2 may play in S. cerevisiae. Most 
importantly, it lays a basis for considering the combination of amino acids that regulate 
cellular growth in yeast. While it was shown that the ratio of leucine relative to a subset 
of amino acids is sensed in regulating growth, the composition of this subset of amino 
acids has yet to be identified. Moving forward, identifying the amino acids that are 
sensed with leucine has the largest implications in understanding amino acid regulation of 
cellular growth. Additionally, identifying the role that WHI2 plays in growth regulation 
by amino acids could have implications in improving health, especially in situation where 
growth is improperly regulated. By transforming constitutively active or suppressed 
proteins in the TOR pathway to see their effect on growth in the Δwhi2 strain could 
provide more information about the role of Whi2 in the TOR pathway. For example, if 
transforming a constitutively active Gtr1 protein into a whi2 knockout strain rescues the 
overgrowth phenotype would imply that Whi2 is upstream of Gtr1 in the TOR pathway. 
In particular, a better understanding of WHI2’s by looking at the effect on growth by 
adding constitutively active or inactive constructs of proteins known in the upstream 
TOR pathway to the Δwhi2 strain. Similar experiments have been done by previous 
members in the lab, in particular a project pursued by a rotation student looking at the 
relation between WHI2 and Gtr1.  
Elucidating the amino acids involved in signaling TOR activation could have 
interesting implications in health due to the multiple roles that TOR plays in health. 




tumorigenesis [6], it has also been shown to have a role in epilepsy, where human 
mutations in the mTORC1 inhibitors TSC1/2 promote epilepsy [55, 56]. In the realm of 
infectious diseases, activating mTORC1 has been shown to regulate T-helper cell 
differentiation [66]. If the amino acids involved in activating TORC1 could be 
determined, it may be possible to utilize different amino acid combinations to encourage 
Th1 or Th2 differentiation. This could be potentially useful to induce appropriate immune 
responses against certain pathogens, especially in cases of chronic infections. In some 
cases, T-cell exhaustion can lead to a shift from the Th1 driven pathogen clearance to a 
more Th2 regulated tolerance; a shift back towards a Th1 response could help drive 
clearance of these infections [66].     
Learning more about Whi2 would also provide additional insight into the TOR 
pathway as well. In particular, having shown that Whi2 appears to play a role in glutamic 
acid metabolism, can narrow the pathways that Whi2 is in. Being able to target Whi2’s 
role in the TORC1 pathway could be have similar implications on health and disease as 
mentioned above. In addition to understanding Whi2 in the context of TOR, 
understanding the role of Whi2 in general would provide information into the functions 
of it’s human analogs, the KCTD proteins. As mutations in one of the KCTD proteins, 
KCTD7, results in progressive myoclonic epilepsy (EPM3) in humans, understanding 
Whi2 may provide a better understanding of how mutations in KCTD7 result in epilepsy 
[58, 59]. Additionally, if TOR plays a role in development of epilepsy through KCTD7, 
understanding the interactions between amino acids, TOR and Whi2 may provide a 




Understanding the role of Whi2 in amino acid sensing and TOR activation could 
have wide implications in health. Aside from the experiments outlined above, more work 
would be needed to gain the necessary knowledge for an impact on health to be made 
through this work. Regardless, with the limited knowledge surrounding both amino acid 
sensing and the cellular function of Whi2 the results provide a better understanding and 
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